BioVascular Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

BioVascular General Information

Description

Developer of drugs and devices designed to commercialize novel cardiovascular therapeutics for significant unmet medical needs. The company's devices control intimal hyperplasia associated with vascular procedures and control factors associated with cardiovascular morbidity and mortality, develop drugs for either hemodialysis access grafts or peripheral bypass grafting, helping medical clinics with the treatment and prevention of vascular diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Drug Discovery
Corporate Office
  • 12230 El Camino Real
  • Suite 100
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioVascular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 02-Jan-2013 0000 Completed Out of Business
3. Later Stage VC (Series C) 07-Feb-2008 000.00 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Nov-2007 $4.09M $8.09M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 11-Jul-2005 $4M $4M 000 Completed Startup
To view BioVascular’s complete valuation and funding history, request access »

BioVascular Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series B 0,000,000 00.000000 00 00 00 00 00 00.000
Series A 4,000,000 $0.001000 8% $1 $1 1x $1 17.81%
To view BioVascular’s complete cap table history, request access »

BioVascular Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs and devices designed to commercialize novel cardiovascular therapeutics for significant unmet medical
Biotechnology
San Diego, CA
4 As of 2020
0000
00000000 00 0000

000000

gna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris n
0000000000000
South San Francisco, CA
00 As of 0000
00000
00000 0000-00-00
00000000000 00000

000000

t dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
Santa Cruz, CA
0 As of 0000
00.00
0000000000 0 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioVascular Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
MicroCures Venture Capital-Backed Santa Cruz, CA 0 00.00 0000000000 0 00.00
Unity Biotechnology Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
Aquinnah Venture Capital-Backed Cambridge, MA 00 0000 0000000000 0000
Imbria Pharmaceuticals Venture Capital-Backed Boston, MA 0 000.00 00000000000 000.00
You’re viewing 5 of 51 competitors. Get the full list »

BioVascular Patents

BioVascular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2011524416-A Controlled release compositions of drugs that reduce circulating levels of platelets and methods therefor Active 16-Jun-2008 0000000000 0
JP-5788315-B2 Controlled release compositions of drugs that reduce circulating levels of platelets and methods therefor Inactive 16-Jun-2008 0000000000
US-9381198-B2 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor Inactive 16-Jun-2008 0000000000 000
JP-5985719-B2 Controlled release compositions of drugs that reduce circulating levels of platelets and methods therefor Inactive 16-Jun-2008 0000000000
GB-0905567-D0 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor Active 16-Jun-2008 A61K9/1676
To view BioVascular’s complete patent history, request access »

BioVascular Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioVascular Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Revitus 10-Sep-2007 0000000000 Drug Discovery 0000 0000
To view BioVascular’s complete acquisitions history, request access »

BioVascular FAQs

  • When was BioVascular founded?

    BioVascular was founded in 2005.

  • Who is the founder of BioVascular?

    John Parrish Ph.D and Paul Glidden Ph.D are the founders of BioVascular.

  • Where is BioVascular headquartered?

    BioVascular is headquartered in San Diego, CA.

  • What is the size of BioVascular?

    BioVascular has 4 total employees.

  • What industry is BioVascular in?

    BioVascular’s primary industry is Biotechnology.

  • Is BioVascular a private or public company?

    BioVascular is a Private company.

  • What is BioVascular’s current revenue?

    The current revenue for BioVascular is 000000.

  • How much funding has BioVascular raised over time?

    BioVascular has raised $19M.

  • Who are BioVascular’s competitors?

    Neurona Therapeutics, MicroCures, Unity Biotechnology, Aquinnah, and Imbria Pharmaceuticals are some of the 51 competitors of BioVascular.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »